89 results about "Candida albicans infection" patented technology

The invention discloses a drug combination for treating dermatosis. The combination is prepared by the following raw materials with certain parts by weight: Galla Chinensis 6-12, Cortex Pseudolaricis 12-24, Radix Sophorae Flavescentis 15-30, Cortex Phellodendri 12-24, Fructus Kochiae 15-30, powdered Sulphur 10-20, Radix Isatidis 8-16, Radix Stemonae 10-20, powdered Calamina 12-24, Hibiscus mutabilis L 8-16, Typhonium gigante um Engl. 10-20, pure Realgar 15-26, Rhizoma Polygonati 10-15, Cinnabaris 8-14, Borneolum, Dexamethasone Tablets 0.25-0.5 or Triamcinolone Acetonide Tablets 0.25-0.5, and Vaseline 1000-2000. The drug combination of the invention belongs to the external-use skin liniment. Years of tests prove that the invention has the advantages of effective and deep disinfection, quick effect and more than 90 percent of effective rate. The invention is applicable for treatment of colpomycosis, mycotic vaginitis and Candida albicans infection; for disinfection and sterilization of skin sensibility and pruritus; and for treatment of foot and hand tinea, tinea manuum, dermatophytosis and balanitis.

The invention discloses a traditional Chinese medicine preparation for treating candida albicans infection diseases. The traditional Chinese medicine preparation comprises the following ingredients in parts by weights: 6 to 10 parts of golden cypress, 6 to 10 parts of coptis chinensis, 6 to 10 parts of skullcap, 3 to 8 parts of cortex pseudolaricis, 3 to 8 parts of cortex dictamni, 3 to 8 parts of hibiscus syriacus, 3 to 8 parts of gallnut, 3 to 6 parts of fructus kochiae and 3 to 6 parts of fructus cnidii. The recipe of the traditional Chinese medicine preparation has the advantages that the cure rate on the chronic candida albicans infection diseases is high, the effect taking speed is high, the disease cannot easily recur after the cure, the patients have no pain, the treatment cost is low, and in addition, no toxic or side effect is caused on the body.

The invention relates to Chinese herbal medicine toothpaste containing a dragon's blood extract and a preparation method thereof, belonging to the technical field of preparation processes of Chinese herbal medicine toothpaste of articles for daily life. The Chinese herbal medicine toothpaste containing the dragon's blood extract is characterized by comprising the following components in percentageby weight: 40-46 percent of calcium carbonate, 6-10 percent of sodium bicarbonate, 0.7-0.8 percent of carrageenan, 0.7-0.8 percent of sodium carboxymethylcellulose, 12-14 percent of glycerol, 14-16 percent of sorbitol, 2-3 percent of sldium lauryl sulfate, 0.1-0.3 percent of saccharin, 0-0.2 percent of potassium sorbate, 1-1.5 percent of strawberry essence, 0.25-0.5 percent of dragon's blood extract and the balance of water. Because the toothpaste contains a dragon's blood active component, the toothpaste has the effects of preventing oral ulcer, preventing oral diseases caused by candida albicans infection besides the function of cleaning teeth.

The invention discloses 3,5-diaryl pyrazole or 3,4-diaryl pyrazole derivative and application thereof. The 3,5-diaryl pyrazole or 3,4-diaryl pyrazole derivative is prepared from compound which is shown in a formula (I), a formula (II), a formula (III) or a formula (IV) or pharmaceutical-acceptable salt of the compound. A formula of the 3,5-diaryl pyrazole or 3,4-diaryl pyrazole derivative is shownin a following image, wherein R1, R2, R3, R4 and R5 are respectively and independently chosen from hydrogen atom, hydroxy, nitro, amino, alkoxy or ester group with a C1 to C10 alkyl substituent group; alkyl in the alkoxy is a C1 to C10 alkyl; R is independently chosen from hydrogen atom, 2-ethoxy, acetyl, phenyl, benzoyl, p-methoxyphenyl, 4-trifluoromethoxy, 2-cyanoethyl or C1 to C10 alkyl. The 3,5-diaryl pyrazole derivative or the 3,4-diaryl pyrazole derivative can be applied to preventing and treating fungal infection; especially, application in treating candida albicans infection and reversing fluconazole drug resistance has good development value.

The invention discloses an external agent and formula of chitose derivant to treat skin and mucosa candida albicans infection, which is characterized by the following: forming chelate through combining partial or all Ag, Zn and Cu ion and carrier chitose molecule; adopting ''multiple target point'' typed coordinating action; mixing natural antioxidant such as essential oil, polyphenol material and so on with high-density alkanoate or hydroxylated acid and surface activator.

The invention discloses an application of wedelolactone in preparing anti-candida albicans medicines. According to the invention, candida albicans is taken as a test object by the inventor so as to screen out a compound which is efficient, low in toxicity and can avoid easy generation of drug resistance, discovering that the wedelolactone can take an excellent inhibitory effect on adhesion, a mycelium formation rate, bio-film formation and pathogenicity of candida albicans. Moreover, the compound, which is relatively low in toxicity, can avoid influence to growth of human cells, and meanwhile,the compound can avoid influence to normal growth of the candida albicans, showing that the compound, instead of killing the candida albicans, can take effects on the candida albicans strains by inhibiting the adhesion, mycelium formation, bio-film formation and pathogenicity of the candida albicans, therefore, drug resistance can be prevented from causing easily. The wedelolactone has a good application prospect in the development of novel anti-fungal medicines, and in particular in the aspect of developing anti-candida albicans infection medicines.

The invention relates to psoralen schiff base derivatives and an application. The compounds are 4-methyl-7-hydroxycoumarin (which is an intermediate 1), 4-methyl-7-hydroxyethoxycoumarin (which is an intermediate 2), 4-methyl-7-formylmethoxycoumarin (which is an intermediate 3), 5-methyl-7H-furan[3,2-g]benzopyran-7-one (which is a compound 4), 7-oxo-7H-furan[3,2-g]benzopyran-5-formaldehyde (which is a compound 5), and a compound 6a-6k. The fact that the 11 psoralen schiff base derivatives affect generation of melanin in mouse B16 cells and inhibit candida albicans, escherichia coli, and staphylococcus aureus is studied. The resultant compounds 6a-6b, 6d-6f and 6j-6k can be applied to prepare medicines for treating vitiligo in the clinic. The obtained psoralen schiff base derivatives can be used for preparing medicines for treating candida albicans infection in the clinic, and the compounds 6b-6c, 6e-6h and 6h-6k can be used for preparing medicines for treating staphylococcus aureus infection in the clinic.

The invention discloses application of Heterophyllin B to anti-candida-albicans drug preparing. Candida albicans serves as a test object, an efficient and low-toxic compound which is not prone to drugresistance generation is screened, and it is discovered that the Heterophyllin B has good inhibiting effect on adhesion and pathogenicity of the candida albicans. The toxicity of the Heterophyllin Bis small, and growth of human cells is not influenced; meanwhile, normal growth of the candida albicans is not influenced, it is indicated that the effect of the Heterophyllin B on candida albicans strains does not mainly depend on killing candida albicans, and depends on inhibiting the adhesion and the pathogenicity of the candida albicans, and therefore the drug resistance is not prone to generation. The Heterophyllin B has good application prospects in development of novel antifungal drugs, particularly, has good application prospects in the development aspect of anti-candida-albicans infection drugs.

The present invention relates to lactobacillus plantarum. The name of the lactobacillus plantarum is lactobacillus plantarum 021, the classification name of the lactobacillus plantarum is lactobacillus plantarum, the preservation number of the lactobacillus plantarum is CGMCC No.22169, the preservation date of the lactobacillus plantarum is April 12, 2021, and the preservation unit of the lactobacillus plantarum is China General Microbiological Culture Collection Center, Institute of Biology, Chinese Academy of Sciences, No.3, No.1 Yard, West Beichen Road, Chaoyang District, Beijing. The lactobacillus plantarum disclosed by the invention has better acid-resistant, cholate-resistant, acid-producing and hydrogen peroxide-producing capabilities. The lactobacillus plantarum has a good adhesion effect on cervical epithelial cells, and meanwhile has a good capability of inhibiting candida albicans and staphylococcus aureus and high antibiotic anti-sensitivity. In addition, the lactobacillus plantarum has an inhibiting effect on candida albicans infectious vaginosis.

Three hemoglobin-response genes in the pathogenic yeast Candida albicans are disclosed. The expression of these genes is specifically induced when the organism is exposed to hemoglobin during disseminated infections. The invention relates to the nucleic acid and amino acid sequences of these hemoglobin-response genes. The invention also relates to diagnostic methods, kits and compositions which employ the nucleic acid and amino acid sequences of the invention.

The invention discloses a primer and a probe for quantitatively detecting Candida Albicans and an application of the primer and the probe. Nucleotide sequences of the primer are shown in sequences 3 and 4 in a sequence table; and a nucleotide sequence of the probe is a sequence 5 in the sequence table. The primer and the probe for quantitatively detecting Candida Albicans and the application of the primer and the probe have the benefits as follows: a group of specific primer and probe sequences for Candida Albicans are provided for qualitative and quantitative detection of Candida Albicans; the Candida Albicans DNA (deoxyribonucleic acid) content in a to-be-detected sample can be accurately quantified by extracting DNA in the to-be-detected sample and combining a real-time fluorescence quantitative PCR (polymerase chain reaction) detection technology; and the primer and the probe can be used for qualitatively and quantitatively analyzing Candida Albicans DNA carried by a patient infected with fungal in clinic and scientific research, have important significance on judgment of Candida Albicans infection, therapeutic effect evaluation and dynamic observation of illness, and simultaneously play an important role in the field of clinical medicine detection.

The invention provides a preparation method of trichomonas pigeon and candida albicans bivalent egg yolk antibody powder and an application thereof. The preparation method comprises the following steps: obtaining trichomonas pigeon and candida albicans bacterial liquid; inactivating trichomonas to obtain an inactivated trichomonas antigen, and inactivating candida albicans to obtain an inactivatedcandida albicans antigen; preparing a bivalent inactivated vaccine from the two inactivated antigens and a glucan adjuvant, and immunizing egg laying hens; collecting immunized eggs, separating egg yolk, removing fat components in the egg yolk by using poloxamer, concentrating filtrate by using a hollow fiber ultrafiltration membrane to obtain a concentrated antibody, adding maltodextrin, and carrying out low-temperature freeze drying to obtain the trichomonas pigeon and candida albicans bivalent egg yolk antibody powder. The titer of the egg yolk antibody powder is far higher than the binding titer of any single egg yolk antibody, the egg yolk antibody powder has a remarkable effect of preventing and treating trichomonad and candida albicans infection, and oral ulcer and craw ulcer caused by infection of homing pigeons, racing pigeons, meat pigeons, pearl trichomonad and candida albicans can be effectively prevented and treated by feeding the egg yolk antibody powder.

The present invention relates to specificity determination and application of one section of candida albicans DNA sequence, and belongs to the field of biomedicine. Through gene data base data search and analysis, the specificity and PCR amplification primer of one section of candida albicans DNA sequence is determined, and the sequence length is 241 bp. By means of PCR amplification and cloning of women's genital tract candida albicans infection sample, the sequence is obtained and sequenced to obtain the result the same as the predicted. Biological informatics and gene chip hybrid analysis proves the specificity of the sequence to candida albicans. The present invention is used as probe and PCR amplification detection sequence for gene chip diagnosis for candida albicans.

The invention discloses an antisense oligonucleotide sequence against candida albicans infection and its use, screening an antisense oligonucleotide SEQ ID No:1 and its derivative using the core pseudoknot of candida albicans type I introne ribozyme as the targets, thus repressing the growth of the candida albicans. Test result shows that the antisense oligonucleotide can strongly repress the shearing reactivity of the candida albicans, and can result in the death of the candida albicans cells.

The invention discloses a compound with anti-Candida albicans activity, a preparation method and application thereof. The compound has a structural formula shown as formula (I) or (II) in the specification. The invention not only provides a new compound, and also the compound can be used for preparation of anti-Candida albicans infection drugs, therefore the development and application prospects are broad.

The invention discloses a candida albicans attenuated strain. The candida albicans attenuated strain is a candida albicans hof1 / hof1 deleted strain which is not expressed by an HOF1 gene. The invention further discloses an application of the candida albicans attenuated strain without the HOF1 gene in preparation or screening of candida albicans treatment drugs. The candida albicans treatment drugscan be prepared by making the HOF1 gene not expressed through RNA interference or a gene recombination method, or the HOF1 protein antagonist is prepared, so that the protein expressed by the HOF1 gene does not play a role. The invention further discloses an application of the candida albicans attenuated strain without the HOF1 gene in toxicity regulation and control. The application comprises the following steps: detecting the influence of HOF1 gene deletion on the survival of Candida albicans in host cells, detecting the toxicity condition of the candida albicans lacking HOF1, and detectingthe influence of the HOF1 gene on visceral colonization of Candida albicans. The invention provides a novel medicament and direction for treating candida albicans infection.

The invention discloses a method for screening hypha-state candida albicans virulence related genes. The method comprises the following steps of: firstly, obtaining the candida albicans growing in a hypha phase by adopting a hypha induction experiment, then, analyzing the transcriptome difference of the candida before and after hypha induction by using a transcriptome sequencing method (RNA-seq), screening virulence related genes, and then, detecting and analyzing respective damage conditions of different host cells infected by the candida albicans by adopting a gram staining method and a cell proliferation rate; and finally, analyzing the difference of virulence gene expression after different types of host cells are infected by the candida by using a reverse transcription-fluorescent quantitative PCR method (qRT-PCR). According to the method, the associated relationship between hypha formation and some virulence factors of the candida can be defined; potential virulence related genes which are differentially activated when different cells are infected by the candida are screened out; and evidence is provided for illuminating different molecular mechanisms of candida infected hosts and screening high-specificity and high-reliability candida virulence genes for diagnosis.

The present invention relates to the technical field of medical bioengineering, and provides an anti-Candida albicans cell wall protein Och1 monoclonal antibody, a polypeptide for preparing the monoclonal antibody, a hybridoma cell line for secreting the monoclonal antibody, and applications of the monoclonal antibody, the polypeptide and the hybridoma cell line in preparation of Western Blot or immunohistochemical Candida albicans infection detection reagents or kits, and in preparation of drugs for prevention or treatment of Candida albicans infections.

The invention relates to ATM fusion protein. 9 amino acids of the T-cell epitope of C. albicans Als3 are connected to the front of the amino acid sequence of S. aureus MntC fusion protein through a Linker, and the amino acid sequence of the fusion protein is shown in SEQ ID No. 1. In the invention, the T-cell epitope of Als3 is fused with the MntC protein so as to prepare the recombinant ATM fusion protein, and immunogenicity study is conducted on the ATM fusion protein. It is verified through results that organisms are induced to produce better immune response and resistance to S. aureus infection and a better immune protection effect after the T-cell epitope of Als3 is fused with the MntC protein, and MntC-induced effects of immune-protection and resistance to S. aureus infection are enhanced significantly through the T-cell epitope of Als3; and meanwhile, the ATM fusion protein also has certain effect of resistance to C. albicans infection, and is ideal candidate fusion protein forpreparation of reagents with resistance to S. aureus infection and C. albicans infection, and the fusion protein has better immunogenicity, and is capable of inducing the organisms to produce good effects of immune protection.

The invention discloses a beta-1,2-D-oligomeric mannose peptide-protein conjugate shown in the formula I and a preparation method and application thereof. In the formula, n is 0 or 1 or 2, and R is carrier protein KLH or HSA. Alpha-D-glucose and alanine resin serve as raw materials, beta-1,2-D-oligomeric mannose peptide is synthesized, the beta-1,2-D-oligomeric mannose peptide is coupled with the carrier protein, and the corresponding beta-1,2-D-oligomeric mannose peptide-protein conjugate is obtained. The prepared compound serves as an anti-candida albicans vaccine to immunize mice, the result shows that the compound can induce the organism to generate high immune response, immunogenicity of the beta-1,2-D-oligomeric mannose peptide-protein conjugate is highest, generated immune serum can be bonded with a candida albicans cell surface antigen, therefore, the effect of resisting candida albicans infection can be achieved, and the beta-1,2-D-oligomeric mannose peptide-protein conjugate has high application value.

The invention relates to coumarin phenyl isoxazole derivatives and applications thereof. 4'-hydroxyl chalcone is taken as the raw materials. 4'-hydroxyl chalcone reacts with bromomethyl isoxazole with different substituent groups in the presence of potassium carbonate to generate 15 coumarin phenyl isoxazole derivatives. At the same time, the influence on generation of melanin in B16 cells of mice and inhibition effect on three bacteria (candida albicans, escherichia coli, and staphylococcus aureus) of 15 coumarin phenyl isoxazole derivatives are also observed. The results of leukoderma resistant experiments show that compared with a negative control, 15 compounds (6a-6o) can all promote the generation of melanin in B16 cells; and compared with a positive control, the compounds (6b-6f and 6j-6o) has a better effect on promoting the generation of melanin. The antibacterial results show that compounds (6d-6f, 6i, and 6l-6n) has an inhibiting effect on candida albicans; and the coumarin phenyl isoxazole derivatives (6d-6f, 6i, and 6l-6n) can be used to prepare drugs for treating leukoderma or candida albicans infection in clinic.

The invention relates to a candida albicans attenuated live vaccine for preventing candida albicans infection as well as a preparation method and application thereof. The vaccine is a candida albicans strain which contains a candida albicans GPI7 and is lack of a whole-genome function, so that candida albicans infection can be effectively prevented and candida albicans infection survival rate is effectively prolonged, and therefore, the candida albicans attenuated live vaccine can be used for preparing attenuated live vaccine for preventing the candida albicans infection.

The invention belongs to the technical field of medicines, and relates to an application of a 2-substituted anthraquinone derivative in treatment of candida albicans infection. Candida albicans can cause infection of the tissues and organs of a host or any part of the skin surface and can be adhered to the surfaces of various medical devices, and many diseases caused by the candida albicans are related to biofilm formation. Experiments prove that 2-ethylanthraquinone, 2-methylanthraquinone, 2-tert-butylanthraquinone and 2-hydroxyanthraquinone have an inhibiting effect on biofilm formation of the candida albicans and can reduce the metabolic activity of biofilm cells, and the 2-ethylanthraquinone also has an effect of inhibiting mycelia formation of the candida albicans. It is proved that the 2-substituted anthraquinone derivative has a good application prospect in preparation of a medicine for treatment of the candida albicans infection.

The invention relates to Chinese herbal medicine toothpaste containing a dragon's blood extract and a preparation method thereof, belonging to the technical field of preparation processes of Chinese herbal medicine toothpaste of articles for daily life. The Chinese herbal medicine toothpaste containing the dragon's blood extract is characterized by comprising the following components in percentage by weight: 40-46 percent of calcium carbonate, 6-10 percent of sodium bicarbonate, 0.7-0.8 percent of carrageenan, 0.7-0.8 percent of sodium carboxymethylcellulose, 12-14 percent of glycerol, 14-16 percent of sorbitol, 2-3 percent of sldium lauryl sulfate, 0.1-0.3 percent of saccharin, 0-0.2 percent of potassium sorbate, 1-1.5 percent of strawberry essence, 0.25-0.5 percent of dragon's blood extract and the balance of water. Because the toothpaste contains a dragon's blood active component, the toothpaste has the effects of preventing oral ulcer, preventing oral diseases caused by candida albicans infection besides the function of cleaning teeth.

An animal model infected by candida albicans where the primary infection is the local abscess in the ear and is accompanied by the infection of candida albicans in all organs. The method is to inject the candida albicans into the subcutaneous of the ear of a rabbit and the concentration of the candida albicans is 1X105 / ml-1X1010 / ml. By doing so, not only the local abscess in the ear is formed, but all organs are infected through blood circulation. In this invention, the model is easy to obtain; the local abscess in the ear can be observed conveniently; the two ears can be compared and the infection of all the organs can be detected at the same time. Thus, the present invention provides a simple and convenient animal model for developing new methods and medicines for the treatment of candida albicans.

The invention provides a polypeptide for inhibiting proliferation of candida albicans and application of the polypeptide in mouthwash, and belongs to the technical field of mouthwash. The polypeptide for inhibiting proliferation of the candida albicans comprises a polypeptide A with an amino acid sequence shown as Lys-Arg-Leu-Phe-Lys-Lys-Leu and a polypeptide B with an amino acid sequence shown as Asp-Leu-Ile-Trp-Lys-Leu-Leu. The polypeptide can be specifically combined with the candida albicans, the function of the polypeptide can be closed, and proliferation of the candida albicans is inhibited. The polypeptide is applied to the mouthwash, the antibacterial and anti-inflammatory effects of the mouthwash can be further improved, and oral candida albicans infection can be prevented.

To provide a novel antigenic protein and a nucleic acid encoding the antigenic protein, which are useful for prophylaxis, treatment and diagnosis of diseases caused by fungi including Candida albicans. An antigenic protein characterized in that the antigenic protein is recognized by antiserum derived from a mammal having Candida albicans-infection resistance; and a nucleic acid encoding an antigenic protein which is recognized by antiserum derived from a mammal having Candida albicans-infection resistance.

The invention relates to the technical field of preparation of animal models, and specifically discloses a construction method of a post-transplantant candida albicans pulmonary infection mouse model. The construction method comprises the following steps: selecting a male C57BL / 6J mouse at the age of six to eight weeks as a donator, a male Balb / c mouse at the age of six to eight weeks as a receptor, and ciclosporin A as an immunosuppressor to construct a mouse skin transplantation model; and dropping 200 mu l of 5*10<5> CFU / ml candida albicans suspension into the body of the mouse suffering from lower back skin transplantation operation 7 days after the skin transplantation operation to obtain the post-transplantant candida albicans pulmonary infection mouse model. According to the construction method of the post-transplantant candida albicans pulmonary infection mouse model, the prepared mouse model is closer to the actual occurrence condition of post-transplantant fungal infection of a clinical patient; in addition, the model is stable; moreover, the method is simple and fast; a large number of stable mouse infection models can be obtained at a time for researchers to use in relevant study on clinical problems.

The invention relates to an application of ervophenol in preparation of an anti-candida albicans drug. The invention particularly discloses the application of ervophenol in preparation of antifungal drugs, and fungi comprise candida albicans. Experiments prove that the ervophenol has a remarkable inhibition effect on the growth of the candida albicans, and also has a good inhibition effect on the adhesion, hypha formation, biofilm formation and toxicity of the candida albicans, so that the effect of the ervophenol on resisting candida albicans strains does not mainly depend on killing the candida albicans, and the infection ability and pathogenicity of the candida albicans are mainly inhibited by inhibiting the adhesion, hypha formation, biofilm formation and toxicity of the candida albicans. Therefore, when the ervophenol is used for treating infectious diseases caused by the candida albicans, drug resistance is not easy to generate. In conclusion, the ervophenol has a good application prospect in the development of novel antifungal drugs, especially in the preparation of drugs for preventing and / or treating Candida albicans infection.